Work

Clinical efficacy of azacitidine in the treatment of middle- and high-risk myelodysplastic syndrome in middle-aged and elderly patients: A retrospective study

Year: 2025

Type: article

Abstract: Objective The aim of this study was to explore the efficacy and safety of azacitidine (AZA) in middle-aged and elderly patients with myelodysplastic syndrome (MDS). Methods The clinical data of 59 middle-aged and elderly patients with middle- and high-risk MDS, who attended our hospital from April 2019 to January 2024, were retrospectively analyzed and were divided into an observation group (AZA) and a control group (conventional supportive treatment) according to the treatments, and the patients in the two groups were evaluated for their clinical efficacy and safety. Results The overall response rate of the observation group was 66.67%. In terms of blood cells, the observation group’s blood cell level after four courses of treatment was significantly higher than that of the control group ( P < 0.05). In terms of lactate dehydrogenase (LDH), the level of LDH decrease after four courses of treatment in the observation group was significantly better than that in the control group ( P < 0.05). The safety of both groups was good. Conclusions AZA is safe and effective in the treatment of high risk MDS in middle and old age patients.

Source: Open Medicine

DOI: 10.1515/med-2025-1151

Authors: Liang Li, Jianjun Bian, Yuxuan Su, Chunchun Zhang

Institution: The Second Affiliated Hospital of Bengbu Medical College

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,373